top of page
Search

GLP-1 pill beats injections, mitochondria fix, vaping's cancer verdict, and five other things worth your time this week.

Jun 22
4 min read

Week of June 22nd, 2026: Seven crucial research findings for your longevity strategy this week. Evidence-graded. No unnecessary details.

1. The GLP-1 Pill Is Here — And It Beats the Shot

Eli Lilly's oral GLP-1, orforglipron (brand name Foundayo), outperformed oral semaglutide across all primary and key secondary endpoints in the landmark ACHIEVE-3 head-to-head Phase 3 trial, published in The Lancet. Unlike current oral semaglutide, Foundayo requires no fasting window and no water restrictions, a meaningful compliance advantage. Across three ACHIEVE trials, it produced clinically meaningful reductions in A1C, non-HDL cholesterol, systolic blood pressure, and triglycerides. A separate Phase 2b trial for AstraZeneca's elecoglipron showed 10.5% weight loss at 26 weeks in type 2 diabetes patients, presented at the American Diabetes Association 2026 Scientific Sessions. The era of the GLP-1 pill has formally begun.

2. GLP-1 Drugs May Cut Breast Cancer Risk by 30%

A large observational study found women taking GLP-1 receptor agonists, the medication class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were approximately 30% less likely to develop breast cancer. The mechanism is not yet fully established. Proposed drivers include adipose tissue reduction (excess fat drives estrogen synthesis), direct anti-inflammatory action on breast tissue, and improved insulin sensitivity. Some researchers suggest GLP-1 receptors on breast cells may have direct anti-proliferative effects, this remains under active investigation. What's clear: the metabolic benefits of this drug class continue to expand beyond weight and glucose control.

3. Alzheimer's and Parkinson's: A New Target Emerges

Researchers at Baylor College of Medicine published findings in Nature Communications showing that tubulin, the protein that assembles your cell's internal microtubule transport network, can redirect Tau and alpha-synuclein proteins away from forming the toxic clumps that characterize Alzheimer's and Parkinson's disease. Both conditions involve the accumulation of these misfolded proteins, and existing drug strategies have largely focused on clearing or blocking them after aggregation begins. This approach works upstream: steering the proteins toward productive cellular function before aggregation occurs. Published June 2026, Nature Communications. Early-stage research; no human trials yet.

4. Vaping Likely Causes Lung and Oral Cancer — Major Review Confirms

A comprehensive review led by UNSW Sydney, published in the journal Carcinogenesis, concluded that nicotine-based e-cigarettes are likely to cause cancers of the lung and oral cavity. The evidence base spans three levels: human biomarker data showing DNA damage, oxidative stress, and tissue inflammation; animal studies producing lung tumors in exposed mice; and laboratory experiments documenting cellular injury and disruption of cancer-suppression pathways. A critical secondary finding: most smokers who switch to vaping continue using conventional cigarettes simultaneously, remaining in what researchers call 'dual-use limbo.' Vaping as a harm-reduction strategy for smokers is not supported by the current evidence base.

5. Half of Adults Over 65 Actually Improve With Age

A Yale School of Public Health study published in Geriatrics (March 2026) followed more than 11,000 adults aged 65 and older for up to 12 years using the Health and Retirement Study dataset. Finding: nearly half showed measurable improvement in cognitive function, physical function, or both — with many gains exceeding clinically meaningful thresholds. Roughly 32% improved cognitively and 28% improved physically. The most reliable predictor of improvement was not genetics or baseline health status. It was how people thought about aging itself. Individuals with positive aging beliefs were significantly more likely to improve on both dimensions. The myth that aging is synonymous with irreversible decline is not supported by longitudinal data.

6. The Mitochondrial Energy Crisis Has a Name — and a Dietary Fix

A Nature Communications paper from the Leibniz Institute on Aging identified declining phosphatidylcholine (PC) synthesis as a key driver of mitochondrial network fragmentation and energy loss during normal aging. Phosphatidylcholine makes up roughly 40–50% of every biological membrane and is essential for the structural flexibility mitochondria need to maintain their energy-distribution networks. As PC production falls with age, mitochondria fragment, lose connectivity, and produce less ATP. The intervention signal: boosting dietary PC restored late-life mitochondrial integrity in aging nematodes within two days. Human cell culture results were consistent. PC is naturally present in eggs, liver, soybeans, and sunflower lecithin. Supplemental phosphatidylcholine is widely available and inexpensive. Whether dietary PC supplementation produces equivalent mitochondrial benefits in humans at scale remains to be established in controlled trials.

7. Senescent Cell Clearance + Regenerative Therapy = 70% Lifespan Increase in Preclinical Models

Immorta Bio published peer-reviewed preclinical findings showing that combining senolytic therapy, drugs that clear senescent ('zombie') cells, with regenerative interventions produced a greater than 70% lifespan increase in animal models. This is the largest preclinical longevity signal reported to date using a combination approach. The finding suggests these two strategies act synergistically: senolytics remove the cellular burden that drives chronic inflammation and tissue dysfunction, while regenerative therapies replenish functional cell populations. Whether this translates to meaningful human lifespan or healthspan extension is unknown. No human trials have been initiated. The preclinical data, however, represents a meaningful proof-of-concept for combination longevity strategy.


Have a great week,

Dr. Smith and Winston

References

1. Lilly's oral GLP-1 orforglipron versus oral semaglutide in type 2 diabetes. The Lancet. 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-delivered-superior-blood-sugar

2. AstraZeneca elecoglipron Phase 2b SOLSTICE trial. The Lancet. June 2026. https://www.healthline.com/health-news/astrazeneca-oral-glp-1-weight-loss-blood-sugar-diabetes

3. GLP-1 use linked to lower breast cancer incidence. Penn Medicine. 2026. https://www.pennmedicine.org/news/glp-1-use-linked-to-lower-breast-cancer-incidence

4. Tubulin prevents toxic brain protein clumps linked to Alzheimer's and Parkinson's. Nature Communications. June 2026. https://www.sciencedaily.com/releases/2026/06/260620100432.htm

5. Major review finds vaping likely causes lung and oral cancer. Carcinogenesis. June 2026. https://www.sciencedaily.com/releases/2026/06/260619020520.htm

7. Aging-associated decline of phosphatidylcholine synthesis is a malleable trigger of natural mitochondrial aging. Nature Communications. April 2026. https://www.nature.com/articles/s41467-026-71508-7

8. Immorta Bio preclinical combination longevity therapy findings. Longevity Technology. Week 25, 2026. https://longevity.technology/unlocked/longevity-technology-unlocked-news-roundup-week-25-2026/

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a qualified physician before initiating any new health protocol. Individual results vary.

 
 
 

Comments

Commenting on this post isn't available anymore. Contact the site owner for more info.
bottom of page